Pro-Dex (PDEX) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
13 Jun, 2025Executive summary
Fiscal 2024 net sales rose 17% year-over-year to $53.8 million, driven by higher sales and repair revenue from the largest customer.
Operating income increased 25% to $7.2 million for the year, reflecting strong sales and gross profit growth.
Net income for the year was $2.1 million, down from $7.1 million in fiscal 2023, due to $4.1 million in unrealized investment losses versus $3.9 million gains last year.
Fourth quarter net sales grew 41% year-over-year to $15.0 million, with operating income up 46% to $2.4 million.
CEO highlighted successful growth despite operational transitions and announced a new Director of Operations for fiscal 2025.
Financial highlights
Q4 gross profit increased 22% to $4.1 million, but gross margin declined to 27% from 32% due to price pressures and higher indirect labor.
Full-year gross profit rose 14% to $14.6 million, with operating expenses up 6% to $7.4 million, mainly from higher R&D costs.
Q4 net income was $1.6 million ($0.46/diluted share), up slightly from $1.5 million ($0.42/diluted share) in Q4 2023.
Full-year diluted EPS was $0.60, down from $1.95 in fiscal 2023.
Segment performance
Revenue growth primarily attributed to increased repair and new unit sales to the largest customer, with $3.6 million more in repair revenue and $3.5 million more in new unit sales year-over-year.
Latest events from Pro-Dex
- Strong sales, new products, and investment gains boosted earnings and cash flow.PDEX
Q2 202629 Jan 2026 - Shareholders to vote on director elections, auditor, executive pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Shareholders to vote on board elections, auditor ratification, and executive pay amid record growth.PDEX
Proxy Filing1 Dec 2025 - Annual meeting seeks votes on directors, auditor, pay, and equity plan extension.PDEX
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and say-on-pay vote set for November 21, 2024.PDEX
Proxy Filing1 Dec 2025 - Revenue and net income surged on strong device sales and investment gains, but margin fell.PDEX
Q1 202630 Oct 2025 - Revenue and profit surged on orthopedic product shipments, but inventory controls remain a risk.PDEX
Q2 202516 Oct 2025 - Revenue up 24% and net income quadrupled in fiscal 2025, with strong outlook for 2026.PDEX
Q4 20254 Sep 2025 - Net income rebounded to $2.5M on 25% sales growth and improved gross margin.PDEX
Q1 202513 Jun 2025